Aflac Tops Trading Volume Rankings as Mixed Earnings and Yen Headwinds Weigh on Shares

Market Snapshot

Shares of Aflac Inc. (AFL) closed at $123.90 on Thursday, August 7, 2026, marking a decline of 1.62% for the trading day. The stock’s performance was characterized by significant trading activity, with total turnover reaching $0.30 billion. This volume ranked first among all stocks in the market for the day, indicating heightened investor attention and liquidity surrounding the insurer’s recent financial disclosures. The after-hours trading session initially saw shares drop further to $123.90, reflecting a 2.18% decline from the previous close, as market participants digested the mixed results of the company’s second-quarter earnings report. Despite the daily pullback, Aflac shares have demonstrated resilience over the broader period, having gained approximately 13.9% year-to-date, slightly outperforming the S&P 500’s gain of 12.8% during the same timeframe. The high trading volume suggests that institutional and retail investors are actively reassessing the company’s valuation in light of the latest quarterly data and forward-looking guidance.

Key Drivers

The primary catalyst for Aflac’s recent price movement was the release of its second-quarter 2026 earnings results, which presented a mixed narrative of operational strength overshadowed by financial headwinds. Adjusted earnings per share came in at $1.75, missing the Zacks Consensus Estimate of $1.77 per share by 1.13%. This represented a slight deterioration from the $1.78 per share reported in the same quarter of the previous year. The earnings miss was part of a broader trend, as the company has surpassed consensus EPS estimates in only one of the last four quarters. While the top-line revenue of $4.22 billion beat the consensus estimate of $4.19 billion by 0.89%, it still reflected a 6.9% year-over-year decline from the $4.54 billion recorded in Q2 2025. This "double miss" on earnings and year-over-year revenue contraction has tempered investor enthusiasm, contributing to the stock’s downward pressure.

A significant drag on profitability stemmed from lower net investment income and unfavorable foreign exchange movements. Adjusted net investment income declined 9.6% year-over-year to $937 million, a trend exacerbated by a stronger U.S. dollar impacting the company’s substantial Japanese operations. The Aflac Japan segment, which contributes the majority of adjusted revenues, saw its adjusted revenues dip 12.6% year-over-year to $2.2 billion. Net earned premiums in Japan slipped 12.7% to $1.5 billion, and new annualized premium sales fell 5.6% to $123 million. The sales decline was partly attributed to a high prior-year sales base for the Miraito cancer insurance product, although this was partially offset by strong growth in refreshed Tsumitasu savings-type life insurance and Anshin Palette products. These international headwinds weighed heavily on the consolidated bottom line, despite cost controls.

Conversely, the Aflac U.S. segment provided a notable counterbalance to the international weakness. U.S. adjusted revenues grew 2.5% year-over-year to $1.8 billion, beating consensus estimates by 0.3%. Net earned premiums in the U.S. advanced 2.3% to $1.5 billion, driven by higher sales and sustained strong policy persistency. The unit’s sales rose 2.6% year-over-year to $349 million, supported by robust demand for group voluntary benefits and network dental and vision products. The U.S. segment’s expense ratio improved to 36.1%, down 20 basis points year-over-year, demonstrating effective cost management even as the total benefit ratio widened to 49.5%. This domestic strength has been a key pillar of the company’s year-to-date outperformance, yet it was insufficient to fully offset the declines in the Japanese market.

Management’s capital deployment and dividend policy offered some support to the stock’s valuation. Aflac returned $1.3 billion to shareholders in the second quarter through $983 million in share repurchases and $309 million in dividends. The board also declared a third-quarter dividend of $0.61 per share, maintaining the company’s 43-year streak of annual dividend increases. This commitment to capital returns, combined with a strong balance sheet featuring total investments and cash of $103 billion, underscores the company’s financial stability. Additionally, Aflac executed $4.8 billion in portfolio repositioning trades expected to boost net investment income by over $50 million annually, signaling proactive management of its investment portfolio amidst changing market conditions.

Looking ahead, the sustainability of Aflac’s stock performance will largely depend on management’s commentary during earnings calls and the trajectory of earnings estimate revisions. The company has maintained its full-year guidance, projecting a benefit ratio of 60-63% for Aflac Japan and 48-52% for Aflac U.S. The current Zacks Rank for the stock remains a #3 (Hold), indicating that shares are expected to perform in line with the broader market in the near future. Investors will be closely monitoring how consensus estimates for the coming quarters adjust to the recent earnings data, as empirical research shows a strong correlation between estimate revisions and near-term stock movements. The interplay between persistent U.S. growth and the recovery of Japanese sales will be critical in determining whether Aflac can resume its upward trajectory in the equity markets.